These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 27003093

  • 1. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity.
    Marinelli L, Mori L, Canneva S, Colombano F, Currà A, Fattapposta F, Bandini F, Capello E, Abbruzzese G, Trompetto C.
    Int Clin Psychopharmacol; 2016 Jul; 31(4):232-9. PubMed ID: 27003093
    [Abstract] [Full Text] [Related]

  • 2. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
    Paolicelli D, Direnzo V, Manni A, D'Onghia M, Tortorella C, Zoccolella S, Di Lecce V, Iaffaldano A, Trojano M.
    J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
    [Abstract] [Full Text] [Related]

  • 3. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R.
    Clin Neuropharmacol; 2018 Jul; 41(5):171-176. PubMed ID: 30024443
    [Abstract] [Full Text] [Related]

  • 4. A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.
    Marinelli L, Balestrino M, Mori L, Puce L, Rosa GM, Giorello L, Currà A, Fattapposta F, Serrati C, Gandolfo C, Abbruzzese G, Trompetto C.
    BMJ Open; 2017 Sep 07; 7(9):e016843. PubMed ID: 28882919
    [Abstract] [Full Text] [Related]

  • 5. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    Squintani G, Donato F, Turri M, Deotto L, Teatini F, Moretto G, Erro R.
    J Neurol Sci; 2016 Nov 15; 370():263-268. PubMed ID: 27772772
    [Abstract] [Full Text] [Related]

  • 6. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec 15; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
    Collin C, Davies P, Mutiboko IK, Ratcliffe S, Sativex Spasticity in MS Study Group.
    Eur J Neurol; 2007 Mar 15; 14(3):290-6. PubMed ID: 17355549
    [Abstract] [Full Text] [Related]

  • 9. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J, Feneberg W, Meier M, Pöllmann W.
    Int J Neurosci; 2014 Sep 15; 124(9):652-6. PubMed ID: 24392812
    [Abstract] [Full Text] [Related]

  • 10. Cannabinoids in multiple sclerosis: A neurophysiological analysis.
    Vecchio D, Varrasi C, Virgilio E, Spagarino A, Naldi P, Cantello R.
    Acta Neurol Scand; 2020 Oct 15; 142(4):333-338. PubMed ID: 32632918
    [Abstract] [Full Text] [Related]

  • 11. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
    Gras A, Broughton J.
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec 15; 16(6):771-779. PubMed ID: 26750641
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
    Maniscalco GT, Aponte R, Bruzzese D, Guarcello G, Manzo V, Napolitano M, Moreggia O, Chiariello F, Florio C.
    Neurol Sci; 2018 Jan 15; 39(1):97-102. PubMed ID: 29052091
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.
    Bethoux FA, Farrell R, Checketts D, Sahr N, Berwaerts J, Alexander JK, Skobieranda F.
    Mult Scler Relat Disord; 2024 Sep 15; 89():105740. PubMed ID: 39106541
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
    Trojano M, Vila C.
    Eur Neurol; 2015 Sep 15; 74(3-4):178-85. PubMed ID: 26571097
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P, Henze T, Zettl UK.
    Eur Neurol; 2014 Sep 15; 72(1-2):95-102. PubMed ID: 24943098
    [Abstract] [Full Text] [Related]

  • 19. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
    Vermersch P, Trojano M.
    Eur Neurol; 2016 Sep 15; 76(5-6):216-226. PubMed ID: 27732980
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.